ciprofloxacin and Bacterial Eye Infections studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Research Excerpts

Excerpt	Relevance	Reference
"This study aimed to evaluate the clinical efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis refractory to amikacin therapy."	9.08	Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis. ( Hu, FR; Luh, KT, 1998)
"3% monotherapy is equivalent clinically and statistically to standard therapy (fortified tobramycin-cefazolin) for the treatment of bacterial corneal ulcers and produces significantly less discomfort."	9.08	Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. ( Adenis, JP; Badrinath, SS; Caldwell, DR; Eiferman, RA; Hyndiuk, RA; Katz, HR; Klauss, V; Reddy, MK; Rosenwasser, GO; Santos, CI, 1996)
"Although topical antibiotics have been used as antimicrobial prophylaxis after ocular surgery, recent studies have determined that intracameral cefuroxime at the end of surgery significantly reduce the risk to suffer an infection and suggest that the use of topical antibiotics in the prophylaxis of infectious postoperative endophthalmitis (IPOE) is controversial."	7.88	Infectious postoperative endophthalmitis after cataract surgery performed over 7 years. The role of azithromycin versus ciprofloxacin eye drops. ( Barceló-Vidal, J; Cartagena-Guardado, Y; Castilla-Martí, M; Fernández-Sala, X; Grau, S; Martínez-Palmer, A; Tuñí-Picado, J, 2018)
" aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1."	7.74	A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007)
"To determine the effectiveness of intravitreal triamcinolone acetonide in the management of bacterial endophthalmitis."	7.73	Intravitreal triamcinolone acetonide in the management of exogenous bacterial endophthalmitis. ( Das, T; Pathengay, A; Shah, GY; Sharma, S, 2006)
"Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis."	7.73	Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005)
"Both moxifloxacin and ciprofloxacin performed significantly better than control in the treatment of Pseudomonas aeruginosa keratitis (P=0."	7.73	Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. ( Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H, 2005)
"3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin."	7.73	Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005)
"To examine how age affects the risk of developing a white corneal precipitate during ciprofloxacin therapy for bacterial keratitis and to explore the effect of a white precipitate on rates of clinical improvement and cure."	7.72	Corneal ciprofloxacin precipitation during bacterial keratitis. ( Abshire, RL; Wilhelmus, KR, 2003)
"3% ciprofloxacin in Staphylococcus aureus keratitis."	7.72	Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. ( Garg, P; Rao, GN; Sharma, S; Sharma, V, 2004)
"Lomefloxacin was compared with ciprofloxacin in different rabbit keratitis models."	7.71	Lomefloxacin is an effective treatment of experimental bacterial keratitis. ( Gordon, YJ; Kowalski, RP; Romanowski, EG; Yates, KA, 2001)
"We compared levofloxacin with ciprofloxacin and ofloxacin using the in vitro susceptibilities of Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) keratitis isolates."	7.71	An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. ( Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK, 2001)
"To determine ciprofloxacin resistance of corneal isolates of Pseudomonas and to review the clinical response to topical therapy in cases of ciprofloxacin-resistant Pseudomonas keratitis, where medical therapy was begun with 0."	7.70	Ciprofloxacin-resistant Pseudomonas keratitis. ( Garg, P; Rao, GN; Sharma, S, 1999)
" This study, employing an experimental rabbit model of Staphylococcus keratitis, compared the effectiveness of two commonly prescribed formulations of fluoroquinolones to an experimental formulation, ciprofloxacin with polystyrene sulfonate (ciprofloxacin-PSS)."	7.70	Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998)
"The authors compare the intravitreal efficacy of ciprofloxacin, vancomycin and imipenem, in treating experimental Bacillus cereus endophthalmitis."	7.69	Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem. ( Alfaro, DV; Bevin, AA; Hudson, SJ; Laughlin, RM; Mines, M; offele, JJ; Schoderbek, RJ, 1996)
"To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone."	7.69	Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. ( Chung, KH; Kim, IT; Koo, BS, 1996)
"36%) tobramycin for the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus keratitis during early and late stages of infection."	7.69	Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. ( Callegan, MC; Engel, LS; Hill, JM; O'Callaghan, RJ, 1994)
"36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively."	7.68	Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993)
"To compare the efficacy of ciprofloxacin hydrochloride ointment with that of ciprofloxacin drops for treatment of experimental Pseudomonas keratitis, rabbit eyes were infected by intrastromal injection of 10(3) colony-forming units (CFU) log-phase P."	7.68	Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1993)
"Ciprofloxacin has been proposed for the systemic treatment of endophthalmitis."	7.68	The role of ciprofloxacin in endophthalmitis therapy. ( Eller, AW; Karenchak, LM; Kowalski, RP, 1993)
"Ciprofloxacin is a fluoroquinolone antimicrobial agent inhibiting bacterial DNA gyrase, with good in vitro and in vivo activity against many Gram-positive and Gram-negative ocular pathogens."	6.68	Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. ( Chang, SW; Hu, FR; Tsai, AC; Tseng, MC, 1995)
"Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity."	5.29	The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996)
"Bacterial keratitis (BK) presentations are often treated using the commercially available second-generation fluoroquinolones ciprofloxacin 0."	5.22	The clinical treatment of bacterial keratitis: A review of drop instillation regimes. ( Essex, RW; Maddess, T; Pearce, JG, 2022)
"This study aimed to evaluate the clinical efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis refractory to amikacin therapy."	5.08	Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis. ( Hu, FR; Luh, KT, 1998)
"3% monotherapy is equivalent clinically and statistically to standard therapy (fortified tobramycin-cefazolin) for the treatment of bacterial corneal ulcers and produces significantly less discomfort."	5.08	Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. ( Adenis, JP; Badrinath, SS; Caldwell, DR; Eiferman, RA; Hyndiuk, RA; Katz, HR; Klauss, V; Reddy, MK; Rosenwasser, GO; Santos, CI, 1996)
"Although topical antibiotics have been used as antimicrobial prophylaxis after ocular surgery, recent studies have determined that intracameral cefuroxime at the end of surgery significantly reduce the risk to suffer an infection and suggest that the use of topical antibiotics in the prophylaxis of infectious postoperative endophthalmitis (IPOE) is controversial."	3.88	Infectious postoperative endophthalmitis after cataract surgery performed over 7 years. The role of azithromycin versus ciprofloxacin eye drops. ( Barceló-Vidal, J; Cartagena-Guardado, Y; Castilla-Martí, M; Fernández-Sala, X; Grau, S; Martínez-Palmer, A; Tuñí-Picado, J, 2018)
"The purpose of this study was to evaluate ciprofloxacin-releasing silicone hydrogel contact lens materials in vitro and in vivo for the treatment of microbial keratitis."	3.80	In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses. ( Hui, A; Jones, L; Willcox, M, 2014)
"Retrospective review of all patients with suspected endophthalmitis after intravitreal injections treated with intravitreal antibiotics (teicoplanin and ciprofloxacin) at a referral centre between January 2003 and December 2010."	3.78	Endophthalmitis following intravitreal injections. ( Heimann, H; Irigoyen, C; Morphis, G; Stappler, T; Ziahosseini, K, 2012)
"To analyse the spectrum of bacterial keratitis isolates and their in vitro antibiotic susceptibilities over a 10-year period in Oxford, UK; and to compare the in vitro efficacy of ciprofloxacin with that of the combination of gentamicin and cefuroxime over the same period."	3.77	In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review. ( Bowler, IC; Hornby, SJ; Orlans, HO, 2011)
" aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1."	3.74	A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007)
"Both moxifloxacin and ciprofloxacin performed significantly better than control in the treatment of Pseudomonas aeruginosa keratitis (P=0."	3.73	Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. ( Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H, 2005)
"Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis."	3.73	Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005)
"To determine the effectiveness of intravitreal triamcinolone acetonide in the management of bacterial endophthalmitis."	3.73	Intravitreal triamcinolone acetonide in the management of exogenous bacterial endophthalmitis. ( Das, T; Pathengay, A; Shah, GY; Sharma, S, 2006)
" Twelve days later, she was diagnosed with posterior scleritis and treated with oral ciprofloxacin."	3.73	Posterior scleritis secondary to Pseudomonas aeruginosa keratitis. ( Dastjerdi, M; Fahim, K; Houghton, O; Mian, SI, 2005)
"3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin."	3.73	Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005)
" The patient was asymptomatic for a month, but the abscess reactivated and was treated with Vancomycin and Ciprofloxacin administered intravenously."	3.72	[Recurrence of bacterial endophthalmitis after penetrating keratoplasty]. ( Domínguez, I; García Serrano, JL; Serrano Laborda, D, 2004)
"To examine how age affects the risk of developing a white corneal precipitate during ciprofloxacin therapy for bacterial keratitis and to explore the effect of a white precipitate on rates of clinical improvement and cure."	3.72	Corneal ciprofloxacin precipitation during bacterial keratitis. ( Abshire, RL; Wilhelmus, KR, 2003)
"3% ciprofloxacin in Staphylococcus aureus keratitis."	3.72	Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. ( Garg, P; Rao, GN; Sharma, S; Sharma, V, 2004)
"The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin."	3.72	Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003)
" Oral treatment with ciprofloxacine healed the phlebitis and the neuroretinitis, with a residual optic disk pallor."	3.72	[Severe retinal phlebitis in ocular bartonellosis]. ( Arteaga Sánchez, A; Díaz-Valle, D; Miguélez Sánchez, R; Pascual Allen, D; Toledano Fernández, N, 2003)
"Overall, moxifloxacin was the most effective of the four fluoroquinolones in reducing CFU/cornea in the rabbit model of gram-negative keratitis."	3.72	Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. ( Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA, 2004)
"Lomefloxacin was compared with ciprofloxacin in different rabbit keratitis models."	3.71	Lomefloxacin is an effective treatment of experimental bacterial keratitis. ( Gordon, YJ; Kowalski, RP; Romanowski, EG; Yates, KA, 2001)
"Although patients ofNocardia keratitis may respond to other antibiotics, amikacin appears to be a drug of choice."	3.71	Treatment and outcome of nocardia keratitis. ( Garg, P; Rao, GN; Sharma, S; Sridhar, MS, 2001)
"We compared levofloxacin with ciprofloxacin and ofloxacin using the in vitro susceptibilities of Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) keratitis isolates."	3.71	An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. ( Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK, 2001)
"To report a clinical case of a 21-year old male with a severe corneal abscess due to Pseudomonas aeruginosa refractory to intensive treatment with topical Ciprofloxacin."	3.71	[Pseudomonas aeruginosa corneal abscess refractory to fluoroquinolones]. ( Alós Cortés, JI; Arteaga Sánchez, A; Díaz Valle, D; Díaz-Valle, T; Poza Morales, Y; Toledano Fernández, N, 2002)
" This study, employing an experimental rabbit model of Staphylococcus keratitis, compared the effectiveness of two commonly prescribed formulations of fluoroquinolones to an experimental formulation, ciprofloxacin with polystyrene sulfonate (ciprofloxacin-PSS)."	3.70	Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998)
"To determine ciprofloxacin resistance of corneal isolates of Pseudomonas and to review the clinical response to topical therapy in cases of ciprofloxacin-resistant Pseudomonas keratitis, where medical therapy was begun with 0."	3.70	Ciprofloxacin-resistant Pseudomonas keratitis. ( Garg, P; Rao, GN; Sharma, S, 1999)
" In the UK chloramphenicol is commonly recommended as the drug of first choice for the treatment of superficial bacterial eye infections."	3.69	Fluoroquinolones for the eye. ( , 1994)
"Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis."	3.69	Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ, 1995)
"36%) tobramycin for the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus keratitis during early and late stages of infection."	3.69	Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. ( Callegan, MC; Engel, LS; Hill, JM; O'Callaghan, RJ, 1994)
"To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone."	3.69	Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. ( Chung, KH; Kim, IT; Koo, BS, 1996)
"The retinal vasculitis and vitreitis resolved after three weeks of therapy with ciprofloxacin hydrochloride without concomitant anti-inflammatory therapy."	3.69	Intermediate uveitis and retinal vasculitis as manifestations of cat scratch disease. ( Foster, CS; Markomichelakis, N; Soheilian, M, 1996)
" The intraocular pressure, which was 68 mmHg at the beginning was lowered with intravenous and per oral acetatcolamide together with timolol and pilocarpine eyedrops, and because of a narrow anterior chamber, with subsequent laser iridotomies."	3.69	Acute glaucoma and acute corneal oedema in association with tularemia. ( Pärssinen, O; Rummukainen, M, 1997)
"The authors compare the intravitreal efficacy of ciprofloxacin, vancomycin and imipenem, in treating experimental Bacillus cereus endophthalmitis."	3.69	Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem. ( Alfaro, DV; Bevin, AA; Hudson, SJ; Laughlin, RM; Mines, M; offele, JJ; Schoderbek, RJ, 1996)
"36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively."	3.68	Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993)
"Ciprofloxacin has been proposed for the systemic treatment of endophthalmitis."	3.68	The role of ciprofloxacin in endophthalmitis therapy. ( Eller, AW; Karenchak, LM; Kowalski, RP, 1993)
"A rabbit model of Staphylococcus aureus keratitis was developed to study the chemotherapeutic efficacy of ciprofloxacin, vancomycin, and cefazolin."	3.68	Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. ( Callegan, MC; Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1992)
"To compare the efficacy of ciprofloxacin hydrochloride ointment with that of ciprofloxacin drops for treatment of experimental Pseudomonas keratitis, rabbit eyes were infected by intrastromal injection of 10(3) colony-forming units (CFU) log-phase P."	3.68	Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1993)
"Two study arms: 99 patients with bacterial conjunctivitis (A group) and 48 patients awaiting cataract surgery (B group--total 147 subjects in both groups) received ciprofloxacin 0."	2.71	[Clinical efficacy of ciprofloxacin 0.3%9 (Ciloxan) in the treatment of bacterial infections of the external eye segment]. ( Goś, A; Kosatka, M; Stankiewicz, A, 2003)
"The ciprofloxacin eyes were significantly more prone to impaired or delayed wound healing and to the development of corneal haze."	2.69	Epithelial healing rates with topical ciprofloxacin, ofloxacin, and ofloxacin with artificial tears after photorefractive keratectomy. ( Chuang, AZ; Kiang, E; Mitra, S; Patel, GM; Ramesh, N; Yee, RW, 2000)
"Ciprofloxacin is a fluoroquinolone antimicrobial agent inhibiting bacterial DNA gyrase, with good in vitro and in vivo activity against many Gram-positive and Gram-negative ocular pathogens."	2.68	Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. ( Chang, SW; Hu, FR; Tsai, AC; Tseng, MC, 1995)
"Preseptal cellulitis is a serious ocular condition that--if left untreated--has the potential to cross the septal barrier, spread to the posterior orbit, and may result in fatal complications."	2.40	Preseptal cellulitis secondary to Proteus species: a case report and review. ( Gabriel, HM; Sears, JM; Veith, J, 1999)
" Besides, it is very necessary to improve the bioavailability of drugs by enhancing the ocular surface adhesion and corneal permeability."	1.91	Multifunctional Polymer Vesicles for Synergistic Antibiotic-Antioxidant Treatment of Bacterial Keratitis. ( Chen, Q; Chen, Y; Duan, Y; Han, X; Lin, Q; Liu, L; Shen, L; Shi, L, 2023)
"Cefazolin resistance was seen in 13."	1.72	Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers. ( Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T, 2022)
"Nocardia interface keratitis is a rare entity, which can occur after DMEK."	1.51	Management of Nocardia Interface Keratitis After Descemet Membrane Endothelial Keratoplasty. ( Chandrika, TN; Katta, KR; Mansoori, T; Reddy, AK; Srirampur, A, 2019)
"Diagnosis of cat scratch disease was established based on positive serology and accompanying systemic symptoms, after ruling out other causes of retinal artery occlusion."	1.43	Retinal artery occlusion due to Bartonella henselae infection: a case series. ( Amer, R; Eiger-Moscovich, M; Kramer, M; Oray, M; Tabbara, KF; Tugal-Tutkun, I, 2016)
"This organism causes a non-specific purulent conjunctivitis that seems to have a benign course and tends to be responsive to a topical fluoroquinolone."	1.43	Four cases of Raoultella planticola conjunctivitis. ( Caruana, P; Cassar, R; Vassallo, J; Vella, M, 2016)
"In cases of unilateral purulent conjunctivitis, there should be a high clinical suspicion of GC, early swab for PCR and culture, and knowledge of current CDC-recommended antibiotic guidelines."	1.42	Prevalence of gonococcal conjunctivitis in adults and neonates. ( Cassidy, L; Curry, A; Knowles, SJ; McAnena, L, 2015)
"Besifloxacin is a novel fluoroquinolone antibiotic developed to provide alternative coverage for ocular pathogens with current and emerging in vitro and in vivo resistance to present fluoroquinolones and other commonly dispensed ocular antibiotics."	1.39	Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. ( Alfonso, EC; Chang, JS; Flynn, HW; Miller, D, 2013)
"Oculoglandular tularemia is not only suspected in cases who complain of fever, cervical lymphadenopathy and purulent conjunctivitis, it should also be suspected in cases who are admitted to the hospital with acute dacryocystitis, which is a rare component of oculoglandular syndrome."	1.39	Unilateral acute dacryocystitis associated with oculoglandular tularemia: a case report. ( Celik, T; Kosker, M; Turkoglu, EB; Yuksel, D, 2013)
"Gatifloxacin showed lower resistance levels than moxifloxacin."	1.38	[In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012)
"Ciprofloxacin resistance was found in 8 (17."	1.37	Antibiotic resistance in microbial keratitis: ten-year experience of corneal scrapes in the United Kingdom. ( Baker, M; Gurbaxani, A; Nash, J; Shalchi, Z, 2011)
"Levofloxacin 1."	1.36	Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. ( Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM, 2010)
" Oral ciprofloxacin and clindamycin have a similar bioavailability to the i."	1.35	Our experience using primary oral antibiotics in the management of orbital cellulitis in a tertiary referral centre. ( Ataullah, S; Cannon, PS; Leatherbarrow, B; Mc Keag, D; Radford, R, 2009)
"An 11-year-old boy, a known case of lamellar ichthyosis, presented with microbial keratitis."	1.35	Microbial keratitis in a case of lamellar ichthyosis. ( Chaurasia, S; Das, S; Ramamurthy, B, 2008)
"Ciprofloxacin was the most statistically potent fluoroquinolone for Pseudomonas spp."	1.34	In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. ( D'Azevedo, PA; Francisco, W; Oliveira, AD, 2007)
"Ocular nocardiosis is relatively rare among ocular infections."	1.34	Isolation and antimicrobial susceptibility pattern of Nocardia among people with culture-proven ocular infections attending a tertiary care eye hospital in Tamilnadu, South India. ( Abarna Lakshmi, LR; Anita, R; Bhaskar, M; Manikandan, P; Narendran, V; Revathi, R, 2007)
"Treatment with ciprofloxacin and amikacin resolved the ulcer."	1.33	Mycobacterium chelonae keratitis: elucidation of diagnosis through evaluation of smears of fluid from patient's contact lens care system. ( Bottone, EJ; Cho, KW, 2005)
"Ciprofloxacin was not detected by either method in the precipitate obtained from one patient."	1.30	Antibacterial activity of the white precipitate formed on the corneal surface after treatment with ciprofloxacin ophthalmic solution. ( Joseph, PR; Madhavan, HN; Rao, SK; Sulochana, KN, 1999)
"Ciprofloxacin was found very efficient antibacterial medication, giving good results even in difficult cases."	1.30	[Results of therapy using Ciloxan-Alcon in clinical practice]. ( Kankovská, E; Válková, Z; Vymazal, M, 1997)
" These results suggest that either salt of prednisolone, when combined with ciprofloxacin, reduces ocular inflammation without affecting the antimicrobial efficacy of the antibiotic."	1.29	Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ, 1993)
"Ciprofloxacin appears to be an effective single agent in the treatment of ulcerative keratitis."	1.29	Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. ( Abrams, DA; Katz, HR; Parks, DJ; Sarfarazi, FA, 1993)
"Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity."	1.29	The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996)
" We conclude that intravitreally injected ciprofloxacin may be a safe and useful antibiotic in the treatment of aminoglycoside-resistant bacterial endophthalmitis."	1.28	Toxicity and pharmacokinetics of intravitreally injected ciprofloxacin in rabbit eyes. ( Basu, PK; Chisholm, L; Hasany, SM; Rootman, DS; Savage, P, 1992)
"Amikacin was more effective in reducing the number of organisms in corneas infected with ATCC-6841 than in corneas infected with the patient isolate (p = 0."	1.28	Mycobacterium fortuitum keratitis. A comparison of topical ciprofloxacin and amikacin in an animal model. ( Berlin, OG; Bruckner, DA; Holland, GN; Paschal, JF; Phinney, RB; Stevens, RK, 1992)
"This is the first reported case of malakoplakia arising from conjunctiva, although three others have involved the ocular adnexa."	1.28	Medical management of ocular malakoplakia. ( Dickinson, J; Sandford-Smith, JH; Simpson, C; Strong, NP; Young, FI, 1992)
"Ciprofloxacin is a new quinolone antibiotic with a broad spectrum of activity against most aerobic gram-positive and gram-negative bacteria."	1.28	Successful treatment of methicillin-resistant Staphylococcus aureus Keratitis with topical ciprofloxacin. ( Fish, LA; Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Silbernagel, J, 1991)
"Ciprofloxacin was significantly more effective than norfloxacin in reducing the number of bacteria per cornea (P less than 0."	1.28	Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ, 1990)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	58 (29.59)	18.2507
2000's	88 (44.90)	29.6817
2010's	37 (18.88)	24.3611
2020's	13 (6.63)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery[NCT00431028]	Phase 1/Phase 2	140 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to Terminated)
Endophthalmitis Post Intravitreal Injections Comparison EPIIC Trial: Pars Plana Vitrectomy Versus Tap and Inject[NCT04035369]		310 participants (Anticipated)	Interventional	2020-03-01	Recruiting
Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure[NCT00804999]		51 participants (Actual)	Interventional	2008-11-01	Completed
Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs[NCT00392275]	Phase 4	48 participants	Interventional	2002-11-30	Completed
Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis[NCT02717871]	Phase 3	35 participants (Actual)	Interventional	2016-03-31	Completed
Contribution of Fast Molecular Bacterial Identification by Real-time PCR in Managing of Postoperative Acute Endophthalmitis[NCT02850653]		150 participants (Anticipated)	Interventional	2007-11-30	Recruiting
A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity.[NCT00892918]		40 participants (Anticipated)	Interventional	2009-06-30	Not yet recruiting
Intracameral Levofloxacin (0.5%) Versus Intracameral Cefuroxime (1mg/0.1ml) Effect on Corneal Endothelial Cell Count and Morphology in Uneventful Phacoemulsification[NCT04212078]	Phase 1/Phase 2	138 participants (Anticipated)	Interventional	2019-07-29	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	cells/mm^3 (Mean)
	Baseline	Two hours
Non Contact Wearing Using Clear Care	85	87
Overnight Soaking in Optifree	49	51
Overnight Soaking in Optifree Replinish	63	61
Overnight Soaking With Renu	66	65

Article	Year
The clinical treatment of bacterial keratitis: A review of drop instillation regimes. Contact lens & anterior eye : the journal of the British Contact Lens Association, 2022, Volume: 45, Issue:6 Topics: Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratitis; Ofloxacin	2022
Keratitis Caused by Candida parapsilosis and Subsequent Corynebacterium macginleyi Infection: Case Report and Short Review. Eye & contact lens, 2020, Volume: 46, Issue:4 Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Candida parapsilosis; Candidiasis; Ciprofloxacin; Co	2020
Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. The British journal of ophthalmology, 2014, Volume: 98, Issue:11 Topics: Administration, Topical; Anti-Bacterial Agents; Ciprofloxacin; Corneal Ulcer; Eye Infections, Bacter	2014
Infectious keratitis after photorefractive keratectomy. Ophthalmology, 2003, Volume: 110, Issue:4 Topics: Adult; Ciprofloxacin; Corneal Ulcer; Cross Infection; Drug Therapy, Combination; Eye Infections, Bac	2003
Microbial keratitis and vision loss with contact lenses. Eye & contact lens, 2003, Volume: 29, Issue:1 Suppl Topics: Adult; Alcaligenes; Anti-Infective Agents; Ciprofloxacin; Contact Lenses, Extended-Wear; Corneal Ulc	2003
Rapid diagnosis and treatment of mycobacterial keratitis after laser in situ keratomileusis. Journal of cataract and refractive surgery, 2003, Volume: 29, Issue:5 Topics: Amikacin; Bacteriological Techniques; Ciprofloxacin; Clarithromycin; Corneal Ulcer; Diagnostic Techn	2003
Preseptal cellulitis secondary to Proteus species: a case report and review. Journal of the American Optometric Association, 1999, Volume: 70, Issue:10 Topics: Adult; Cellulitis; Ciprofloxacin; Diagnosis, Differential; Drainage; Eye Infections, Bacterial; Eyel	1999
New antibacterial drugs for topical ophthalmic use. Optometry clinics : the official publication of the Prentice Society, 1992, Volume: 2, Issue:4 Topics: Ciprofloxacin; Conjunctivitis, Bacterial; Corneal Ulcer; Drug Therapy, Combination; Eye Infections,	1992

Article	Year
A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery. Investigative ophthalmology & visual science, 2009, Volume: 50, Issue:7 Topics: Aged; Anterior Chamber; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Connective T	2009
Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Archives of ophthalmology (Chicago, Ill. : 1960), 2003, Volume: 121, Issue:9 Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; E	2003
[Clinical efficacy of ciprofloxacin 0.3%9 (Ciloxan) in the treatment of bacterial infections of the external eye segment]. Klinika oczna, 2003, Volume: 105, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Cataract	2003
Microbial keratitis in prospective studies of extended wear with disposable hydrogel contact lenses. Cornea, 2005, Volume: 24, Issue:2 Topics: Adolescent; Adult; Anti-Infective Agents; Bacteria; Ciprofloxacin; Contact Lenses, Extended-Wear; Co	2005
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. American journal of ophthalmology, 2006, Volume: 141, Issue:2 Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Child; Ciprofloxacin;	2006
Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. The British journal of ophthalmology, 2008, Volume: 92, Issue:3 Topics: Administration, Oral; Anti-Bacterial Agents; Aqueous Humor; Cataract Extraction; Ciprofloxacin; Drug	2008
0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Archives of ophthalmology (Chicago, Ill. : 1960), 1993, Volume: 111, Issue:9 Topics: Administration, Topical; Bacteria; Ciprofloxacin; Cornea; Corneal Ulcer; Drug Administration Schedul	1993
Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. Journal of the Formosan Medical Association = Taiwan yi zhi, 1995, Volume: 94, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Ciprofloxacin; Eye Infections, Bacterial; Fem	1995
Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology, 1996, Volume: 103, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria;	1996
Antimicrobial effect of ciprofloxacin, povidone-iodine, and gentamicin in the decontamination of human donor globes. Cornea, 1998, Volume: 17, Issue:1 Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Colony Count, Microbial; Disinfection; Eye; Eye Bank	1998
Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis. Ophthalmology, 1998, Volume: 105, Issue:2 Topics: Administration, Topical; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents;	1998
Epithelial healing rates with topical ciprofloxacin, ofloxacin, and ofloxacin with artificial tears after photorefractive keratectomy. Journal of cataract and refractive surgery, 2000, Volume: 26, Issue:5 Topics: Administration, Topical; Adult; Anti-Infective Agents; Ciprofloxacin; Corneal Topography; Drug Thera	2000
Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea, 2001, Volume: 20, Issue:2 Topics: Adult; Anti-Infective Agents; Bacteria; Ciprofloxacin; Corneal Ulcer; Double-Blind Method; Drug Admi	2001

ciprofloxacin and Bacterial Eye Infections

Research Excerpts

Research

Studies (196)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

HRT Corneal Scan

Reviews

Trials

Other Studies

Authors	Studies
Wang, Y	1
Carion, TW	1
Ebrahim, AS	1
Sosne, G	1
Berger, EA	1
Soni, T	1
Gunasekaran, R	1
Das, S	2
Mitra, S	2
Prajna, NV	2
Prajna, L	1
Sharma, S	10
Mohamed, A	1
Pearce, JG	1
Essex, RW	1
Maddess, T	1
Romano, V	1
Bignotti, S	1
Forbice, E	1
Piccinelli, G	1
Caruso, A	1
Semeraro, F	1
Parmar, GS	1
Meena, AK	1
Borde, P	1
Prasad, S	1
Chen, Q	1
Han, X	1
Liu, L	1
Duan, Y	1
Chen, Y	1
Shi, L	1
Lin, Q	1
Shen, L	1
Zhang, Z	1
Suner, SS	1
Blake, DA	1
Ayyala, RS	1
Sahiner, N	1
Feghhi, M	1
Sharif Makhmalzadeh, B	1
Farrahi, F	1
Akmali, M	1
Hasanvand, N	1
Quan, AV	1
Huang, AM	1
Galor, A	1
Díaz Barrón, A	1
Sanz Gallen, L	1
Hervás Hernandis, JM	1
Tarragó Simón, E	1
Duch-Samper, AM	1
Cornée, C	1
Mainguy, A	1
Coeuru, D	1
Routier, M	1
Lebranchu, P	1
Vabres, B	1
Fejes, I	1
Garcia-Hermosa, P	1
Bodin, A	1
Tabuenca Del Barrio, L	1
Mozo Cuadrado, M	1
Compains Silva, E	1
Aliseda Pérez De Madrid, D	1
Heras Mulero, H	1
Palioura, S	1
Gibbons, A	1
Miller, D	4
OʼBrien, TP	1
Alfonso, EC	3
Spierer, O	1
Taubenslag, KJ	1
Michaels, MG	1
Sylvester, CL	1
Tuñí-Picado, J	1
Martínez-Palmer, A	1
Fernández-Sala, X	1
Barceló-Vidal, J	1
Castilla-Martí, M	1
Cartagena-Guardado, Y	1
Grau, S	1
Srirampur, A	1
Mansoori, T	1
Reddy, AK	2
Katta, KR	1
Chandrika, TN	1
Hazlett, LD	1
Ekanayaka, SA	1
McClellan, SA	1
Francis, R	1
Celik, T	1
Yuksel, D	1
Kosker, M	1
Turkoglu, EB	1
Roy, R	2
Pradeep Kumar, P	1
Malathi, J	2
Swakshyar Saumya, P	1
Krishnendu, N	1
Abhinandan, P	1
Konda, N	1
Motukupally, SR	1
Garg, P	7
Ali, MH	1
Willcox, MD	1
Li, SA	1
Liu, J	1
Xiang, Y	1
Wang, YJ	1
Lee, WH	1
Zhang, Y	1
McDonald, EM	1
Ram, FS	1
Patel, DV	1
McGhee, CN	1
Hui, A	1
Willcox, M	1
Jones, L	2
Sand, D	1
She, R	1
Shulman, IA	1
Chen, DS	1
Schur, M	1
Hsu, HY	1
Bajgrowicz, M	1
Phan, CM	1
Subbaraman, LN	1
McAnena, L	1
Knowles, SJ	1
Curry, A	1
Cassidy, L	1
Fernandes, M	1
Vira, D	1
Medikonda, R	1
Kumar, N	1
Vassallo, J	1
Vella, M	1
Cassar, R	1
Caruana, P	1
Eiger-Moscovich, M	1
Amer, R	1
Oray, M	1
Tabbara, KF	1
Tugal-Tutkun, I	1
Kramer, M	1
Tabatabaei, SA	1
Soleimani, M	1
Behrooz, MJ	1
Sheibani, K	1
Qin, G	1
Zhu, Z	1
Li, S	1
McDermott, AM	1
Cai, C	1
Jensen, MK	2
Fiscella, RG	2
Moshirfar, M	2
Mooney, B	2
Karicherla, P	1
Hobden, JA	9
Lindstrom, RL	1
Holland, EJ	1
Lane, SS	1
McCulley, JP	2
Alam, MR	1
Gopinathan, U	2
Krishnaiah, S	1
Paganelli, F	2
Cardillo, JA	2
Melo, LA	2
Lucena, DR	1
Silva, AA	2
Oliveira, AG	2
Höfling-Lima, AL	1
Nguyen, QD	1
Kuppermann, BD	1
Belfort, R	1
Sengupta, J	1
Khetan, A	1
Saha, S	1
Ganguly, A	1
Pal, D	1
Pizzolitto, AC	1
Scheepers, MA	1
Keel, S	1
Michaelides, M	1
Kowalski, RP	8
Romanowski, EG	6
Mah, FS	3
Shanks, RM	1
Gordon, YJ	6
Subrayan, V	1
Peyman, M	1
Lek Yap, S	1
Mohamed Ali, NA	1
Devi, S	1
Shih, MH	1
Huang, FC	1
Jain, D	1
Carvalho, E	1
Banthia, AK	1
Banerjee, R	1
Lin, HC	1
Ma, DH	1
Chen, YF	1
Yeh, LK	1
Hsiao, CH	1
Orlans, HO	1
Hornby, SJ	1
Bowler, IC	1
Fintelmann, RE	1
Hoskins, EN	1
Lietman, TM	1
Keenan, JD	1
Gaynor, BD	1
Cevallos, V	1
Acharya, NR	1
Shalchi, Z	1
Gurbaxani, A	1
Baker, M	1
Nash, J	1
Irigoyen, C	1
Ziahosseini, K	1
Morphis, G	1
Stappler, T	1
Heimann, H	1
Wong, CA	1
Galvis, V	1
Tello, A	1
Villareal, D	1
Rey, JJ	1
Hooper, CY	1
Lightman, SL	1
Pacheco, P	1
Tam, PM	1
Khan, A	1
Taylor, SR	1
Portero, A	1
Careño, E	1
Real, LA	1
Villarón, S	1
Herreras, JM	1
Chang, JS	1
Flynn, HW	1
Panigrahi, P	1
Pal, SS	1
Nandi, K	1
Patil, A	1
Nigam, E	1
Arora, V	1
Venkata, N	1
Gora, R	1
Chhabra, R	1
Aasuri, MK	1
Parmar, P	3
Salman, A	2
Kalavathy, CM	3
Jesudasan, CA	3
Thomas, PA	3
Donnenfeld, ED	2
O'Brien, TP	3
Solomon, R	2
Perry, HD	2
Speaker, MG	1
Wittpenn, J	1
Díaz-Valle, D	1
Toledano Fernández, N	2
Arteaga Sánchez, A	2
Miguélez Sánchez, R	1
Pascual Allen, D	1
Holden, BA	2
Sweeney, DF	2
Sankaridurg, PR	2
Carnt, N	1
Edwards, K	1
Stretton, S	2
Stapleton, F	1
Daines, BS	1
Vroman, DT	1
Sandoval, HP	1
Steed, LL	1
Solomon, KD	1
Tungsiripat, T	1
Sarayba, MA	2
Kaufman, MB	1
Sweet, PM	2
Taban, M	2
Carpenter, TR	1
McDonnell, PJ	3
Watson, A	1
Sloan, B	1
Wilhelmus, KR	3
Abshire, RL	3
Schlech, BA	1
Lomholt, JA	1
Kilian, M	1
Lee, KY	1
Lim, L	1
Barequet, IS	1
Denton, P	1
Osterhout, GJ	1
Tuli, S	1
García Serrano, JL	1
Domínguez, I	1
Serrano Laborda, D	1
Stankiewicz, A	1
Kosatka, M	1
Goś, A	1
Vedantham, V	2
Ramalingam, K	1
Kaliamurthy, J	2
Thibodeaux, BA	3
Dajcs, JJ	3
Caballero, AR	2
Marquart, ME	3
Girgis, DO	1
O'Callaghan, RJ	14
Rhee, MK	1
Ritterband, DC	2
Hyon, JY	1
Joo, MJ	1
Hose, S	1
Sinha, D	1
Dick, JD	1
Crandall, AS	1
Wallin, T	1
Olson, RJ	1
Sharma, V	1
Rao, GN	7
Jensen, H	1
Zerouala, C	1
Carrier, M	1
Short, B	1
Naduvilath, TJ	1
Aliprandis, E	1
Ciralsky, J	1
Lai, H	1
Herling, I	1
Katz, HR	6
Bottone, EJ	1
Cho, KW	1
Miller, J	1
Oguz, H	1
Ozbilge, H	1
Oguz, E	1
Gurkan, T	1
Dillen, K	1
Vandervoort, J	1
Ludwig, A	1
Shamie, N	1
Reiser, BJ	1
Graff, JM	1
Kesler-Diaz, A	1
Osann, KE	1
Fahim, K	1
Houghton, O	1
Dastjerdi, M	1
Mian, SI	1
Freisberg, L	1
Starr, MB	1
Chee, SP	1
Bacsal, K	1
Duran, N	1
Koc, A	1
Oksuz, H	1
Tamer, C	1
Akaydin, Y	1
Kozlu, T	1
Celik, M	1
Hoffman, PM	1
Poon, A	1
Snibson, GR	1
Donnenfeld, RS	1
Jensen, HG	1
Stein, J	1
Snyder, RW	1
Wittpenn, JR	1
Johnston, KH	1
Prasanth, DA	1
Curi, AL	1
Machado, DO	1
Heringer, G	1
Campos, WR	1
Orefice, F	1
Schornack, MM	1
Peterson, D	1
Sharma, N	1
Sinha, R	1
Singhvi, A	1
Tandon, R	1
Pathengay, A	1
Shah, GY	1
Das, T	1
Yağci, R	1
Oflu, Y	1
Dinçel, A	1
Kaya, E	1
Yağci, S	1
Bayar, B	1
Duman, S	1
Bozkurt, A	2
Manikandan, P	1
Bhaskar, M	1
Revathi, R	1
Anita, R	1
Abarna Lakshmi, LR	1
Narendran, V	1
Su, PY	1
Hu, FR	3
Chen, YM	1
Han, JH	1
Chen, WL	1
Dodds, EM	1
Echandi, LV	1
Puente, SI	1
Kaufman, S	1
Oliveira, AD	1
D'Azevedo, PA	1
Francisco, W	1
Woodward, M	1
Randleman, JB	1
Symes, RJ	1
Catt, CJ	1
Males, JJ	1
Yates, KA	2
Bu, P	1
Riske, PS	1
Zaya, NE	1
Carey, R	1
Bouchard, CS	1
Al-Shakarchi, F	1
Gupta, A	1
Srinivasan, R	1
Kaliaperumal, S	1
Setia, S	1
Chaurasia, S	1
Ramamurthy, B	1
Cantor, LB	1
WuDunn, D	1
Yung, CW	1
Valluri, S	1
Catoira, YP	1
Hoop, JS	1
Morgan, LS	1
Ramos-Esteban, JC	1
Jeng, BH	1
Cannon, PS	1
Mc Keag, D	1
Radford, R	1
Ataullah, S	1
Leatherbarrow, B	1
Lee, SM	1
Kim, MK	1
Lee, JL	1
Wee, WR	1
Lee, JH	1
Afshari, NA	1
Ma, JJ	1
Duncan, SM	1
Pineda, R	1
Starr, CE	1
Decroos, FC	1
Johnson, CS	1
Adelman, RA	1
Diamond, JP	1
White, L	1
Leeming, JP	1
Bing Hoh, H	1
Easty, DL	1
Engel, LS	5
Callegan, MC	7
Reidy, JJ	3
Hill, JM	11
Guzek, JP	1
Chacko, D	1
Kettering, JD	1
Wessels, IF	1
Aprecio, RM	1
Golnik, KC	1
Marotto, ME	1
Fanous, MM	1
Heitter, D	1
King, LP	1
Halpern, JI	1
Holley, PH	1
Probst, LE	1
Brewer, LV	1
Hussain, Z	1
Tokarewicz, AC	1
Lin, R	2
Holland, GN	3
Helm, CJ	2
Elias, SJ	1
Berlin, OG	3
Bruckner, DA	3
Karenchak, LM	3
Eller, AW	1
Lauffenburger, MD	1
Cohen, KL	1
Hyndiuk, RA	2
Caldwell, DR	2
Folkens, AT	2
Godio, LB	1
Maskin, SL	1
Parks, DJ	1
Abrams, DA	1
Sarfarazi, FA	1
Maffett, M	1
O'Day, DM	1
Insler, MS	6
Tsai, AC	1
Tseng, MC	1
Chang, SW	1
Braun, M	1
Jonas, JB	1
Schönherr, U	1
Naumann, GO	1
Bafna, S	1
Lee, AG	2
Kim, IT	1
Chung, KH	1
Koo, BS	1
Leahey, AB	1
Jones, D	1
Soheilian, M	1
Markomichelakis, N	1
Foster, CS	1
Alfaro, DV	2
Hudson, SJ	1
offele, JJ	1
Bevin, AA	1
Mines, M	1
Laughlin, RM	1
Schoderbek, RJ	1
Shimomura, Y	1
Kaufman, SC	1
Laird, JA	1
Cooper, R	1
Beuerman, RW	1
Eiferman, RA	2
Rosenwasser, GO	1
Santos, CI	1
Badrinath, SS	1
Reddy, MK	2
Adenis, JP	1
Klauss, V	1
Davis, J	2
Kim, S	1
Bia, F	1
Bogard, JF	1
Briggs, JW	1
Liggett, PE	2
Válková, Z	1
Kankovská, E	1
Vymazal, M	1
Brancato, R	1
Carones, F	1
Venturi, E	1
Cavallero, A	1
Gesu, G	1
Nadkarni, MS	1
Dasari, S	1
Luh, KT	1
Pärssinen, O	1
Rummukainen, M	1
Moreau, JM	2
Green, LC	1
Chaudhry, NA	1
Tabandeh, H	1
Rosenfeld, PJ	1
Hill, VE	1
Brownstein, S	1
Jackson, WB	1
Mintsioulis, G	1
Kunimoto, DY	1
Oztürk, F	1
Kortunay, S	1
Kurt, E	1
Ilker, SS	1
Inan, UU	1
Basci, NE	1
Kayaalp, O	1
Horgan, SE	1
Matheson, MM	1
McLOUGHLIN-Borlace, L	1
Dart, JK	1
Goldstein, MH	1
Madhavan, HN	1
Rao, SK	1
Joseph, PR	1
Sulochana, KN	1
Sears, JM	1
Gabriel, HM	1
Veith, J	1
Shields, JA	1
Shields, CL	1
Eagle, RC	1
Moster, M	1
Murray, DC	1
Christopoulou, D	1
Hero, M	1
Suhler, EB	1
Lauer, AK	1
Rosenbaum, JT	1
Patel, GM	1
Chuang, AZ	1
Kiang, E	1
Ramesh, N	1
Yee, RW	1
Alexandrakis, G	1
Booth, MC	1
Gilmore, MS	1
Lema, I	1
Gómez-Torreiro, M	1
Rodríguez-Ares, MT	1
Sridhar, MS	2
George, C	1
Selvaraj, S	1
Lu, KL	1
Srinivasan, M	1
Chen, KH	1
Kuang, TM	1
Hsu, WM	1
Pinna, A	1
Sechi, LA	1
Zanetti, S	1
Usai, D	1
Delogu, G	1
Cappuccinelli, P	1
Carta, F	1
Pandya, AN	1
Husted, RC	1
Shah, MK	1
Tabin, G	1
Danenhower, C	1
Reardon, D	1
Dimmig, J	1
McCormick, G	1
Traidej, M	1
Austin, MS	1
Stroman, DW	1
Mather, R	1
Suresh, PS	1
Rootman, DS	2
Díaz Valle, D	1
Alós Cortés, JI	1
Poza Morales, Y	1
Díaz-Valle, T	1
Yolton, DP	1
Savage, P	1
Hasany, SM	1
Chisholm, L	1
Basu, PK	1
Stevens, RK	1
Paschal, JF	1
Phinney, RB	1
Snyder, ME	1
Simpson, C	1
Strong, NP	1
Dickinson, J	1
Young, FI	1
Sandford-Smith, JH	1
el Baba, FZ	1
Trousdale, MD	1
Gauderman, WJ	1
Wagner, DG	1
Hagenah, M	1
Fish, LA	1
Silbernagel, J	1